BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
Number Citing Articles
1 Lee JI, Park KS, Cho IH. Panax ginseng: a candidate herbal medicine for autoimmune disease. J Ginseng Res 2019;43:342-8. [PMID: 31308804 DOI: 10.1016/j.jgr.2018.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
2 Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111. e2. [PMID: 22326435 DOI: 10.1053/j.gastro.2012.01.035] [Cited by in Crossref: 352] [Cited by in F6Publishing: 337] [Article Influence: 35.2] [Reference Citation Analysis]
3 Noth R, Stüber E, Häsler R, Nikolaus S, Kühbacher T, Hampe J, Bewig B, Schreiber S, Arlt A. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease. Journal of Crohn's and Colitis 2012;6:464-9. [DOI: 10.1016/j.crohns.2011.10.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
4 Maharshak N, Plevy SE. A Crohn's Disease Patient Who Does Not Respond to Infliximab: What Is Next? Clinical Gastroenterology and Hepatology 2011;9:1033-8. [DOI: 10.1016/j.cgh.2011.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24-30. [PMID: 23792214 DOI: 10.1016/j.autrev.2013.06.002] [Cited by in Crossref: 201] [Cited by in F6Publishing: 178] [Article Influence: 22.3] [Reference Citation Analysis]
6 Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol. 2013;48:1394-1398. [PMID: 24131338 DOI: 10.3109/00365521.2013.845906] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
7 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 144] [Cited by in F6Publishing: 124] [Article Influence: 28.8] [Reference Citation Analysis]
8 Dwadasi S, Israel A, Rubin DT. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am 2019;29:405-19. [PMID: 31078244 DOI: 10.1016/j.giec.2019.03.001] [Reference Citation Analysis]
9 Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohnʼs Disease. Inflammatory Bowel Diseases 2017;23:1316-27. [DOI: 10.1097/mib.0000000000001203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
10 Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, Davoli M, Addis A. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol 2018;10:203-13. [PMID: 29440933 DOI: 10.2147/CLEP.S150030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Czarnewski P, Parigi SM, Sorini C, Diaz OE, Das S, Gagliani N, Villablanca EJ. Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification. Nat Commun 2019;10:2892. [PMID: 31253778 DOI: 10.1038/s41467-019-10769-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
12 Vedak P, Kroshinsky D, St John J, Xavier RJ, Yajnik V, Ananthakrishnan AN. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther 2016;43:697-704. [PMID: 26806281 DOI: 10.1111/apt.13542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
13 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
14 Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2015;10:37-45. [DOI: 10.1586/17474124.2016.1096198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
15 Actis GC, Pellicano R, Rosina F. Inflammatory bowel diseases: Current problems and future tasks. World J Gastrointest Pharmacol Ther 2014; 5(3): 169-174 [PMID: 25133045 DOI: 10.4292/wjgpt.v5.i3.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
16 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
17 Zator ZA, Cantu SM, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr 2014;38:385-91. [PMID: 24088707 DOI: 10.1177/0148607113504002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
18 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
19 Tun GS, Lobo AJ. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease. Expert Opinion on Drug Metabolism & Toxicology 2014;11:317-27. [DOI: 10.1517/17425255.2015.995166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-64. [PMID: 24796769 DOI: 10.1038/ajg.2014.106] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 11.9] [Reference Citation Analysis]
21 de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Corica D, Romano C. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2017;51:100-110. [PMID: 27636407 DOI: 10.1097/mcg.0000000000000696] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 5.4] [Reference Citation Analysis]
23 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
24 Hu H, Xiang C, Qiu C, Chen Z, Huang S, Liang L, Wang X. Discontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study. Gastroenterology Res 2017;10:92-9. [PMID: 28496529 DOI: 10.14740/gr800w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Triantafyllou K, Beintaris I, Dimitriadis GD. Is there a role for colon capsule endoscopy beyond colorectal cancer screening? A literature review. World J Gastroenterol 2014; 20(36): 13006-13014 [PMID: 25278694 DOI: 10.3748/wjg.v20.i36.13006] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
26 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
27 Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3-13. [PMID: 27862107 DOI: 10.1111/apt.13847] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 17.3] [Reference Citation Analysis]
28 Grover Z, Biron R, Carman N, Lewindon P. Predictors of response to Infliximab in children with luminal Crohn's disease. J Crohns Colitis. 2014;8:739-746. [PMID: 24445015 DOI: 10.1016/j.crohns.2013.12.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
29 Shen H, Lipka S, Katz S. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience. J Crohns Colitis 2014;8:898-9. [PMID: 24434182 DOI: 10.1016/j.crohns.2013.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis 2015;21:1359-67. [PMID: 25989340 DOI: 10.1097/MIB.0000000000000376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
31 Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis 2015;21:323-30. [PMID: 25545378 DOI: 10.1097/MIB.0000000000000264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
32 Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:674-682. [PMID: 23666424 DOI: 10.1007/s00535-013-0829-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 8.2] [Reference Citation Analysis]
33 Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflamm Intest Dis 2018;2:228-35. [PMID: 30221150 DOI: 10.1159/000486786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci 2015;60:3075-84. [PMID: 26044830 DOI: 10.1007/s10620-015-3735-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
35 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016;151:97-109.e4. [PMID: 27039969 DOI: 10.1053/j.gastro.2016.03.037] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
37 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
38 Dassopoulos T, Sninsky CA. Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease. Gastroenterology Clinics of North America 2012;41:393-409. [DOI: 10.1016/j.gtc.2012.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
39 Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín JI, Cabezudo Gil P, Orive Cura V. Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission. Gastroenterología y Hepatología (English Edition) 2016;39:442-8. [DOI: 10.1016/j.gastre.2016.06.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 2016;44:157-69. [PMID: 27218676 DOI: 10.1111/apt.13653] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
41 Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci 2012;57:1013-9. [PMID: 22089254 DOI: 10.1007/s10620-011-1969-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
42 Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666. [PMID: 23357488 DOI: 10.1016/j.cgh.2012.12.035] [Cited by in Crossref: 124] [Cited by in F6Publishing: 112] [Article Influence: 13.8] [Reference Citation Analysis]
43 Gupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, Ananthakrishnan AN. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. Aliment Pharmacol Ther 2016;43:52-60. [PMID: 26541937 DOI: 10.1111/apt.13454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
44 Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016;50:733-741. [PMID: 26535480 DOI: 10.1097/mcg.0000000000000441] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
45 Abraham NS, Richardson P, Castillo D, Kane S. WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2013:S1542-3565(13)01042-2. [PMID: 23891919 DOI: 10.1016/j.cgh.2013.04.051] [Reference Citation Analysis]
46 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
47 Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol 2017;112:120-31. [PMID: 27958281 DOI: 10.1038/ajg.2016.569] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
48 Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther. 2013;37:855-866. [PMID: 23489068 DOI: 10.1111/apt.12284] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
49 Qi S, Duan N, Khan IM, Dong X, Zhang Y, Wu S, Wang Z. Strategies to manipulate the performance of aptamers in SELEX, post-SELEX and microenvironment. Biotechnology Advances 2022. [DOI: 10.1016/j.biotechadv.2021.107902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
50 Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457-478. [PMID: 25110253 DOI: 10.1016/j.gtc.2014.05.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
51 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
52 Kern MD, Ortega Alcaide J, Rentschler ME. Soft material adhesion characterization for in vivo locomotion of robotic capsule endoscopes: Experimental and modeling results. J Mech Behav Biomed Mater 2014;39:257-69. [PMID: 25151447 DOI: 10.1016/j.jmbbm.2014.07.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
53 Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 15.0] [Reference Citation Analysis]
54 Coward S, Heitman SJ, Clement F, Negron M, Panaccione R, Ghosh S, Barkema HW, Seow C, Leung YP, Kaplan GG. Funding a smoking cessation program for Crohn's disease: an economic evaluation. Am J Gastroenterol. 2015;110:368-377. [PMID: 25350768 DOI: 10.1038/ajg.2014.300] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
55 Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7:118-121. [PMID: 25436030 DOI: 10.14740/jocmr1991w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
56 Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 2013;14:853-61. [PMID: 22975794 DOI: 10.1007/s10198-012-0430-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
57 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
58 Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, Cho SJ, Kim SE, Cho KB, Yang SK. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. Intest Res 2019;17:237-43. [PMID: 30727711 DOI: 10.5217/ir.2018.00071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
59 Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, Kudo M. Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis. Sci Rep 2020;10:19186. [PMID: 33154436 DOI: 10.1038/s41598-020-76175-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bonnin P, Coelho J, Pocard M, Levy BI, Marteau P. Anti-TNFα therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active Crohn's disease. J Crohns Colitis 2013;7:451-9. [PMID: 22841134 DOI: 10.1016/j.crohns.2012.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
61 Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT. Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 2017;71:773-7. [PMID: 28225051 DOI: 10.1038/ejcn.2017.10] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
62 Weintraub Y, Mimouni FB, Cohen S. Temporal trends in inflammatory bowel disease publications over a 19-years period. World J Gastroenterol 2014; 20(44): 16745-16749 [PMID: 25469047 DOI: 10.3748/wjg.v20.i44.16745] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
63 Ciccocioppo R, Corazza GR. Mesenchymal stem cells for fistulising Crohn's disease. Lancet 2016;388:1251-2. [PMID: 27477895 DOI: 10.1016/S0140-6736(16)31209-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
64 Rizopoulos T, Papadaki-Petrou H, Assimakopoulou M. Expression Profiling of the Transient Receptor Potential Vanilloid (TRPV) Channels 1, 2, 3 and 4 in Mucosal Epithelium of Human Ulcerative Colitis. Cells 2018;7:E61. [PMID: 29914124 DOI: 10.3390/cells7060061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
65 Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
66 Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? J Crohns Colitis 2017;11:697-705. [PMID: 27838610 DOI: 10.1093/ecco-jcc/jjw203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
67 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
68 Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon JW, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease. J Gastroenterol Hepatol 2019;34:2118-25. [PMID: 31039275 DOI: 10.1111/jgh.14696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Madsen KG, Pottegård A, Hallas J, Kjeldsen J. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease—A Cohort Study. Inflammatory Bowel Diseases 2018;24:2628-33. [DOI: 10.1093/ibd/izy178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
70 Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn’s disease: A retrospective study. Dig Liver Dis. 2014;46:695-700. [PMID: 24893686 DOI: 10.1016/j.dld.2014.04.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
71 Castiglione F, Testa A, Rea M, De Palma GD, Diaferia M, Musto D, Sasso F, Caporaso N, Rispo A. Transmural healing evaluated by bowel sonography in patients with Crohn’s disease on maintenance treatment with biologics. Inflamm Bowel Dis. 2013;19:1928-1934. [PMID: 23835441 DOI: 10.1097/mib.0b013e31829053ce] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
72 Targownik LE, Tennakoon A, Leung S, Lix LM, Nugent Z, Singh H, Bernstein CN. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. Inflammatory Bowel Diseases 2017;23:409-20. [DOI: 10.1097/mib.0000000000001025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
73 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 13.5] [Reference Citation Analysis]
74 Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D’incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V, Saettone S, Tari R, Petruzzellis C, Meucci G, Imperiali G, Guglielmi FW, Mazzuoli S, Caserta L, Caterina Parodi M, Colli A, Ronchetti A, Pugliese D, Geccherle A, Rogai F, Milani S, Renna S, Cassinotti A, Andriulli A, Martino G, Scrivo B, Troncone E, Kohn A, Bertani L, Lorenzon G, Ghione S, Nardone O, Vecchi M, Bertani A, Bosani MA, Bezzio C, Salerno R; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019;25:568-79. [DOI: 10.1093/ibd/izy264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
75 Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, Ting A, McNeill J, Knight R, Santamaria J. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. J Gastroenterol Hepatol. 2015;30:1346-1353. [PMID: 25867770 DOI: 10.1111/jgh.12967] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
76 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
77 Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Kiss T, Wittmann T. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period]. Orv Hetil 2011;152:951-7. [PMID: 21609921 DOI: 10.1556/OH.2011.29128] [Reference Citation Analysis]
78 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
79 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
80 Astier A. [Interchangeability and substitution of biosimilars]. Ann Pharm Fr 2020;78:277-84. [PMID: 32387176 DOI: 10.1016/j.pharma.2020.04.004] [Reference Citation Analysis]
81 O’neill I, Scully C. Biologics in oral medicine: principles of use and practical considerations: Biologics use and practical considerations. Oral Diseases 2012;18:525-36. [DOI: 10.1111/j.1601-0825.2012.01919.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
82 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
83 Phadke VK, Friedman-Moraco RJ, Quigley BC, Farris AB, Norvell JP. Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis: Case report and review of the literature. Medicine (Baltimore) 2016;95:e5082. [PMID: 27759636 DOI: 10.1097/MD.0000000000005082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
84 Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín JI, Cabezudo Gil P, Orive Cura V. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission]. Gastroenterol Hepatol 2016;39:442-8. [PMID: 26948837 DOI: 10.1016/j.gastrohep.2015.11.011] [Reference Citation Analysis]
85 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
86 Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136-143. [PMID: 21953314 DOI: 10.1007/s00535-011-0474-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
87 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
88 Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:840-849. [PMID: 22971016 DOI: 10.1111/apt.12043] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
89 Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Sparrow M, Walsh AJ, Andrews JM; AIBDA. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response: Biologic dose tailoring in Crohn disease. Intern Med J 2015;45:170-7. [DOI: 10.1111/imj.12621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World J Gastroenterol 2020; 26(14): 1554-1563 [PMID: 32327905 DOI: 10.3748/wjg.v26.i14.1554] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-1619. [PMID: 22914296 DOI: 10.1016/s0140-6736(12)60150-0] [Cited by in Crossref: 840] [Cited by in F6Publishing: 408] [Article Influence: 84.0] [Reference Citation Analysis]
92 Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 2017;52:284-90. [DOI: 10.1080/00365521.2016.1250942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
93 Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30. [PMID: 23899685 DOI: 10.1093/cid/cit489] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
94 Law CC, Sasidharan S, Rodrigues R, Nguyen DD, Sauk J, Garber J, Giallourakis C, Xavier R, Khalili H, Yajnik V. Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis. 2016;22:2149-2157. [PMID: 27482978 DOI: 10.1097/mib.0000000000000870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
95 Lykowska-Szuber L, Walczak M, Skrzypczak-Zielinska M, Suszynska-Zajczyk J, Stawczyk-Eder K, Waszak K, Eder P, Wozniak A, Krela-Kazmierczak I, Slomski R, Dobrowolska A. Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease. Front Immunol 2021;12:615539. [PMID: 33767696 DOI: 10.3389/fimmu.2021.615539] [Reference Citation Analysis]
96 Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464-78.e1-5. [PMID: 24267475 DOI: 10.1053/j.gastro.2013.10.046] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 11.5] [Reference Citation Analysis]
97 Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. J Crohns Colitis 2015;9:1032-42. [PMID: 26245216 DOI: 10.1093/ecco-jcc/jjv139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
98 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
99 Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36-49. [PMID: 23063970 DOI: 10.1053/j.gastro.2012.10.003] [Cited by in Crossref: 336] [Cited by in F6Publishing: 319] [Article Influence: 33.6] [Reference Citation Analysis]
100 Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.J Crohns Colitis. 2013;7:958-967. [PMID: 23517933 DOI: 10.1016/j.crohns.2013.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
101 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
102 Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology 2015;51:196-202. [DOI: 10.3109/00365521.2015.1079924] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
103 Kotze PG, Ghosh S, Bemelman WA, Panaccione R. Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intest Res 2017;15:160-5. [PMID: 28522944 DOI: 10.5217/ir.2017.15.2.160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
104 Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
105 Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. Front Immunol 2021;12:646673. [PMID: 34367126 DOI: 10.3389/fimmu.2021.646673] [Reference Citation Analysis]
106 Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol 2019;114:472-82. [PMID: 30410041 DOI: 10.1038/s41395-018-0272-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
107 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
108 Kamata N, Oshitani N, Watanabe K, Watanabe K, Hosomi S, Noguchi A, Yukawa T, Yamagami H, Shiba M, Tanigawa T, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci 2015;60:1382-8. [PMID: 25532505 DOI: 10.1007/s10620-014-3493-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
109 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
110 Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. Aliment Pharmacol Ther 2018;47:346-55. [DOI: 10.1111/apt.14452] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
111 Spencer EA, Dubinsky MC. Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Pediatric Clinics of North America 2017;64:1309-26. [DOI: 10.1016/j.pcl.2017.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Long D, Merlin D. Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease. Nanomedicine (Lond) 2021;16:1741-5. [PMID: 34196224 DOI: 10.2217/nnm-2021-0167] [Reference Citation Analysis]
113 Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 2017;46:162-8. [PMID: 28470787 DOI: 10.1111/apt.14125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
114 Peyrin-biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of Crohn’s disease. Digestive and Liver Disease 2017;49:368-77. [DOI: 10.1016/j.dld.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
115 Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, Amir A, González A, Tripathi A, Chen M, Wu GD, Knight R, Zhou H, Chen Y. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems 2018;3:e00188-17. [PMID: 29404425 DOI: 10.1128/mSystems.00188-17] [Cited by in Crossref: 85] [Cited by in F6Publishing: 52] [Article Influence: 21.3] [Reference Citation Analysis]
116 Helwig U, Lutter F, Koppka N, Schreiber S. Proposal for an anti-TNF-exit strategy based on trough serum level. Biologicals 2017;47:81-5. [PMID: 28400083 DOI: 10.1016/j.biologicals.2017.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
117 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
118 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
119 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
120 Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119 [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
121 Zhuang X, Tian Z, Feng R, Li M, Li T, Zhou G, Qiu Y, Chen B, He Y, Chen M, Zeng Z, Zhang S. Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease. Inflamm Bowel Dis 2020;26:1636-47. [PMID: 33026078 DOI: 10.1093/ibd/izaa253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
122 Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease. J Crohns Colitis 2015;9:1120-6. [PMID: 26351386 DOI: 10.1093/ecco-jcc/jjv156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
123 Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771-1780. [PMID: 25155227 DOI: 10.1038/ajg.2014.242] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 10.8] [Reference Citation Analysis]
124 Annese V, Vecchi M. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis. 2014;46:963-968. [PMID: 25139379 DOI: 10.1016/j.dld.2014.07.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
125 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
126 Lee WS, Azmi N, Ng RT, Ong SY, Ponnampalavanar SS, Mahadeva S, Hilmi I. Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. Intest Res 2017;15:524-8. [PMID: 29142521 DOI: 10.5217/ir.2017.15.4.524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
127 Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am 2014;43:425-40. [PMID: 25110251 DOI: 10.1016/j.gtc.2014.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
128 Zhang T, Xiang J, Cui B, He Z, Li P, Chen H, Xu L, Ji G, Nie Y, Wu K, Fan D, Huang G, Bai J, Zhang F. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget 2017;8:88894-903. [PMID: 29179485 DOI: 10.18632/oncotarget.21491] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
129 Cheng J, Hamilton Z, Smyth M, Barker C, Israel D, Jacobson K. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1762-73. [DOI: 10.1097/mib.0000000000001212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
130 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
131 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
132 Šimurina M, de Haan N, Vučković F, Kennedy NA, Štambuk J, Falck D, Trbojević-Akmačić I, Clerc F, Razdorov G, Khon A, Latiano A, D'Incà R, Danese S, Targan S, Landers C, Dubinsky M, McGovern DPB, Annese V, Wuhrer M, Lauc G; Inflammatory Bowel Disease Biomarkers Consortium. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology 2018;154:1320-1333.e10. [PMID: 29309774 DOI: 10.1053/j.gastro.2018.01.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
133 [DOI: 10.1117/12.2042795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
134 Farkas K, Lakatos PL, Szűcs M, Pallagi-Kunstár &, Bálint A, Nagy F, Szepes Z, Vass N, Kiss LS, Wittmann T, Molnár T. Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20(11): 2995-3001 [PMID: 24659890 DOI: 10.3748/wjg.v20.i11.2995] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
135 Torres J, Cravo M, Colombel JF. Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Port J Gastroenterol 2016;23:153-61. [PMID: 28868451 DOI: 10.1016/j.jpge.2015.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
136 Malíčková K, Ďuricová D, Bortlík M, Hind’oš M, Machková N, Hrubá V, Lukáš M, Zima T, Lukáš M. Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals 2016;44:33-6. [DOI: 10.1016/j.biologicals.2015.09.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
137 Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. BMJ Open 2019;9:e024222. [PMID: 30782731 DOI: 10.1136/bmjopen-2018-024222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
138 Gisbert JP, Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016;111:632-47. [PMID: 27002797 DOI: 10.1038/ajg.2016.54] [Cited by in Crossref: 86] [Cited by in F6Publishing: 71] [Article Influence: 14.3] [Reference Citation Analysis]
139 Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med 2014;2:4. [PMID: 25332980 DOI: 10.3978/j.issn.2305-5839.2013.10.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Yang BL, Chen YG, Gu YF, Chen HJ, Sun GD, Zhu P, Shao WJ. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World J Gastroenterol 2015; 21(8): 2475-2482 [PMID: 25741157 DOI: 10.3748/wjg.v21.i8.2475] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
141 Miclescu AA, Nordquist L, Hysing EB, Butler S, Basu S, Lind AL, Gordh T. Targeting oxidative injury and cytokines' activity in the treatment with anti-tumor necrosis factor-α antibody for complex regional pain syndrome 1. Pain Pract 2013;13:641-8. [PMID: 23336526 DOI: 10.1111/papr.12027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
142 Sorrentino D, Fogel S, Van den Bogaerde J. Surgery for Crohn’s disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol. 2013;7:689-700. [PMID: 24161133 DOI: 10.1586/17474124.2013.842895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
143 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:653-61. [DOI: 10.1093/ecco-jcc/jjy003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
144 Crusio RHJ, Singson SV, Haroun F, Mehta HH, Parenti DM. Herpes simplex virus encephalitis during treatment with etanercept. Scandinavian Journal of Infectious Diseases 2013;46:152-4. [DOI: 10.3109/00365548.2013.849816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
145 Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, Trebble TM. Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology. PLoS One 2013;8:e76532. [PMID: 24204637 DOI: 10.1371/journal.pone.0076532] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
146 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
147 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Savova G, Churchill S, Karlson EW, Murphy SN, Liao KP, Kohane I. Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2016;22:151-8. [PMID: 26332313 DOI: 10.1097/MIB.0000000000000580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
148 Mizoshita T, Tanida S, Kusumoto S, Ozeki K, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol 2012;5:302-6. [PMID: 26182398 DOI: 10.1007/s12328-012-0314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
149 Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2016;63:130-55. [DOI: 10.1097/mpg.0000000000001188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
150 Ananthakrishnan AN. Making sense of clinical predictors. J Gastroenterol Hepatol 2018;33 Suppl 3:7-8. [PMID: 30187548 DOI: 10.1111/jgh.14417] [Reference Citation Analysis]
151 Barber GE, Yajnik V, Khalili H, Giallourakis C, Garber J, Xavier R, Ananthakrishnan AN. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol 2016;111:1816-22. [PMID: 27596696 DOI: 10.1038/ajg.2016.408] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
152 Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778 [PMID: 25944990 DOI: 10.3748/wjg.v21.i16.4773] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
153 Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies: . Inflammatory Bowel Diseases 2013;19:2778-86. [DOI: 10.1097/01.mib.0000435435.91988.b6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
154 Jiang XL, Fan H. Efforts to improve biological treatment of refractory ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2013; 21(15): 1375-1380 [DOI: 10.11569/wcjd.v21.i15.1375] [Reference Citation Analysis]
155 Danese S, Peyrin-biroulet L. Enriching the therapeutic armamentarium for IBD. Nat Rev Gastroenterol Hepatol 2014;11:84-6. [DOI: 10.1038/nrgastro.2013.246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
156 Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320-9. e3. [PMID: 25724455 DOI: 10.1053/j.gastro.2015.02.031] [Cited by in Crossref: 512] [Cited by in F6Publishing: 429] [Article Influence: 73.1] [Reference Citation Analysis]
157 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. J Crohns Colitis 2015;9:238-45. [PMID: 25576753 DOI: 10.1093/ecco-jcc/jjv004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
158 West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F; Oxford IBD Cohort Investigators. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017;23:579-89. [PMID: 28368383 DOI: 10.1038/nm.4307] [Cited by in Crossref: 259] [Cited by in F6Publishing: 254] [Article Influence: 51.8] [Reference Citation Analysis]
159 Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis 2013;19:2021-30. [PMID: 23644824 DOI: 10.1097/MIB.0b013e318281f5c5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
160 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
161 Eberhardson M, Marits P, Jones M, Jones P, Karlen P, Karlsson M, Cotton G, Woznica K, Maltman B, Glise H, Winqvist O. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol 2013;149:73-82. [PMID: 23892544 DOI: 10.1016/j.clim.2013.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
162 Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg 2016; 8(3): 274-283 [PMID: 27022455 DOI: 10.4240/wjgs.v8.i3.274] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
163 Löwenberg M, D’Haens G. Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21. [PMID: 26031830 DOI: 10.1007/s11894-015-0444-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
164 Goyal A, Goyal K, Merola JF. Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. Am J Clin Dermatol 2015;16:179-95. [PMID: 25854805 DOI: 10.1007/s40257-015-0124-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
165 Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, (ICC) RKWDIOCAC. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol 2014; 20(41): 15374-15381 [PMID: 25386087 DOI: 10.3748/wjg.v20.i41.15374] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
166 Saruta M, Papadakis KA. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am 2014;43:581-601. [PMID: 25110260 DOI: 10.1016/j.gtc.2014.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
167 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]
168 Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, Florholmen J, Goll R. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn’s disease. Scand J Gastroenterol. 2013;48:311-319. [PMID: 23302000 DOI: 10.3109/00365521.2012.758773] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
169 Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27. [PMID: 23878167 DOI: 10.1136/gutjnl-2013-305279] [Cited by in Crossref: 329] [Cited by in F6Publishing: 292] [Article Influence: 41.1] [Reference Citation Analysis]
170 Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014; 20(5): 1248-1258 [PMID: 24574799 DOI: 10.3748/wjg.v20.i5.1248] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
171 Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn’s disease. Aliment Pharmacol Ther. 2014;40:1044-1055. [PMID: 25185992 DOI: 10.1111/apt.12940] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
172 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
173 Cha JM, Park DI, Park SH, Shin JE, Kim WS, Yang SK. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients. J Korean Med Sci 2017;32:85-94. [PMID: 27914136 DOI: 10.3346/jkms.2017.32.1.85] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
174 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405. [PMID: 26075832 DOI: 10.1111/apt.13276] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
176 Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 2012;57:472-80. [PMID: 21909990 DOI: 10.1007/s10620-011-1896-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
177 Greener T, Boland K, Steinhart AH, Silverberg MS. The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:458-64. [DOI: 10.1093/ecco-jcc/jjx176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
178 Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. [PMID: 21320139 DOI: 10.1111/j.1365-2036.2011.04598.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
179 Malíčková K, Ďuricová D, Bortlík M, Janatková I, Zima T, Lukáš M. Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. Auto Immun Highlights 2013;4:27-32. [PMID: 26000139 DOI: 10.1007/s13317-012-0045-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
180 Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082-1092. [PMID: 26381802 DOI: 10.1111/apt.13387] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
181 Feagan BG, Lémann M, Befrits R, Connell W, Dʼhaens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude JC, Vermeire S, Rutgeerts P. Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report: . Inflammatory Bowel Diseases 2012;18:152-60. [DOI: 10.1002/ibd.21870] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
182 Moon W, Pestana L, Becker B, Loftus EV, Hanson KA, Bruining DH, Tremaine WJ, Kane SV. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Aliment Pharmacol Ther. 2015;42:428-440. [PMID: 26081839 DOI: 10.1111/apt.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
183 Seo GS, Lee SH. [Emerging Therapies: What Are Promising in the Near Future?]. Korean J Gastroenterol 2018;71:81-8. [PMID: 29471605 DOI: 10.4166/kjg.2018.71.2.81] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011] [Cited by in Crossref: 298] [Cited by in F6Publishing: 250] [Article Influence: 29.8] [Reference Citation Analysis]
185 Squires S, Naismith G, Boal A. Combining NICE guidelines with exclusion criteria to identify patients with Crohn's disease for treatment withdrawal: 12-month prospective cohort study. Gastrointestinal Nursing 2016;14:20-8. [DOI: 10.12968/gasn.2016.14.2.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Dig Dis Sci 2015;60:2762-70. [PMID: 25673037 DOI: 10.1007/s10620-015-3581-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 8.4] [Reference Citation Analysis]
187 de Groof EJ, Cabral VN, Buskens CJ, Morton DG, Hahnloser D, Bemelman WA; research committee of the European Society of Coloproctology. Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines. Colorectal Dis. 2016;18:O119-O134. [PMID: 26847796 DOI: 10.1111/codi.13286] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
188 Mohagheghi Darehranj S, Alatab S, Vahedi H, Sadeghi A, Sima A, Malekzadeh M, Anoshiravani A, Fakheri H, Ebrahimi Daryani N, Mousavi A, Mansour-Ghanaei F, Zahedi MJ, Malekzadeh R. Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. Middle East J Dig Dis 2020;12:12-8. [PMID: 32082516 DOI: 10.15171/mejdd.2020.158] [Reference Citation Analysis]
189 Al Omran Y, Aziz Q. The brain-gut axis in health and disease. Adv Exp Med Biol 2014;817:135-53. [PMID: 24997032 DOI: 10.1007/978-1-4939-0897-4_6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
190 Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of Biosimilars: A European Perspective. BioDrugs 2017;31:83-91. [PMID: 28120313 DOI: 10.1007/s40259-017-0210-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 82] [Article Influence: 20.4] [Reference Citation Analysis]
191 Wang MH, Friton JJ, Raffals LE, Leighton JA, Pasha SF, Picco MF, Cushing KC, Monroe K, Nix BD, Newberry RD, Faubion WA. Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:1036-43. [PMID: 30689765 DOI: 10.1093/ecco-jcc/jjz017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
192 Burke KE, Khalili H, Garber JJ, Haritunians T, McGovern DPB, Xavier RJ, Ananthakrishnan AN. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1840-8. [PMID: 29718226 DOI: 10.1093/ibd/izy083] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
193 West NR, Owens BMJ, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol 2018;88:e12694. [DOI: 10.1111/sji.12694] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
194 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. European Journal of Internal Medicine 2014;25:485-90. [DOI: 10.1016/j.ejim.2014.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
195 Reinisch W, Van Assche G, Befrits R, Connell W, D'haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis 2012;6:248-58. [DOI: 10.1016/j.crohns.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
196 Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1172-83. [DOI: 10.1111/apt.12330] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
197 Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015;13:1103-1110. [PMID: 25478919 DOI: 10.1016/j.cgh.2014.11.026] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
198 Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161 [PMID: 28828193 DOI: 10.4292/wjgpt.v8.i3.155] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
199 Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012; 18(28): 3635-3661 [PMID: 22851857 DOI: 10.3748/wjg.v18.i28.3635] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 125] [Article Influence: 14.0] [Reference Citation Analysis]
200 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
201 Biasi F, Leonarduzzi G, Oteiza PI, Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal. 2013;19:1711-1747. [PMID: 23305298 DOI: 10.1089/ars.2012.4530] [Cited by in Crossref: 118] [Cited by in F6Publishing: 121] [Article Influence: 13.1] [Reference Citation Analysis]
202 Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378. [PMID: 24595615 DOI: 10.1007/s11894-014-0378-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
203 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
204 O'Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol 2019;75:1-11. [PMID: 30187103 DOI: 10.1007/s00228-018-2542-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
205 Lagassé HAD, McCormick Q, Sauna ZE. Secondary failure: immune responses to approved protein therapeutics. Trends Mol Med 2021;27:1074-83. [PMID: 34493437 DOI: 10.1016/j.molmed.2021.08.003] [Reference Citation Analysis]
206 O’neill I, Scully C. Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis: Biologics: oral Crohn’s and OFG. Oral Diseases 2012;18:633-8. [DOI: 10.1111/j.1601-0825.2012.01918.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
207 Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014;49:100-109. [PMID: 23575576 DOI: 10.1007/s00535-013-0803-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
208 Kang B, Choi SY, Choi YO, Kim M, Kim K, Lee J, Choe YH. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn’s Disease Patients Treated With Combined Immunosuppressive Therapy. Journal of Crohn's and Colitis 2018;12:644-52. [DOI: 10.1093/ecco-jcc/jjy021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
209 Linares R, Gutiérrez A, Márquez-galera Á, Caparrós E, Aparicio JR, Madero L, Payá A, López-atalaya JP, Francés R. Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease. Biomedicine & Pharmacotherapy 2022;147:112653. [DOI: 10.1016/j.biopha.2022.112653] [Reference Citation Analysis]
210 Johnson SL, Bartels CM, Palta M, Thorpe CT, Weiss JM, Smith MA. Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study. BMJ Open 2015;5:e008597. [PMID: 26346875 DOI: 10.1136/bmjopen-2015-008597] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
211 Ananthakrishnan AN, Kane SV. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. Gastroenterology 2015;148:877-80. [PMID: 25805424 DOI: 10.1053/j.gastro.2015.03.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
212 Abraham NS, Richardson P, Castillo D, Kane SV. Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1281-7. [DOI: 10.1016/j.cgh.2013.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
213 Sahu P, Vuyyuru SK, Kante B, Agarwal A, Sharma R, Das P, Panwar R, Jain S, Bopanna S, Makharia G, Kedia S, Ahuja V. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian J Gastroenterol 2020;39:388-97. [PMID: 32880844 DOI: 10.1007/s12664-020-01043-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
214 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
215 Moran GW, Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S, Panaccione R. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol 2015; 21(25): 7795-7804 [PMID: 26167079 DOI: 10.3748/wjg.v21.i25.7795] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
216 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Nishiwaki H, Ebi M, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterol Res Pract 2014;2014:687257. [PMID: 24829572 DOI: 10.1155/2014/687257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
217 Viscido A, Capannolo A, Latella G, Caprilli R, Frieri G. Nanotechnology in the treatment of inflammatory bowel diseases. J Crohns Colitis. 2014;8:903-918. [PMID: 24686095 DOI: 10.1016/j.crohns.2014.02.024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
218 Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol 2016;14:1302-9. [PMID: 27189916 DOI: 10.1016/j.cgh.2016.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
219 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 216] [Article Influence: 39.3] [Reference Citation Analysis]
220 Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's Disease in clinical practice. J Gastroenterol Hepatol. 2015;Epub ahead of print. [PMID: 26173493 DOI: 10.1111/jgh.13039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
221 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
222 Zhang ZM, Li W, Jiang XL. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut Liver. 2016;10:262-274. [PMID: 26780088 DOI: 10.5009/gnl15042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
223 Zheng LM, Pang Z. Advances in treatment of Crohn's disease with adalimumab. Shijie Huaren Xiaohua Zazhi 2012; 20(14): 1222-1228 [DOI: 10.11569/wcjd.v20.i14.1222] [Reference Citation Analysis]
224 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
225 Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, Regueiro M, Schwartz DA, Quinn CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015;42:132-44. [PMID: 25812483 DOI: 10.1016/j.cct.2015.03.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
226 Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OØ, Brynskov J. Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol 2016;50:483-9. [PMID: 26166141 DOI: 10.1097/MCG.0000000000000375] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
227 Sozzani S, Abbracchio MP, Annese V, Danese S, De Pità O, De Sarro G, Maione S, Olivieri I, Parodi A, Sarzi-Puttini P. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity 2014;47:287-306. [PMID: 24697663 DOI: 10.3109/08916934.2014.897333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
228 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 12.3] [Reference Citation Analysis]
229 Kohem CL, Bortoluzzo AB, Gonçalves CR, Silva JABD, Ximenes AC, Bértolo MB, Ribeiro SL, Keiserman M, Menin R, Skare TL, Carneiro S, Azevedo VF, Vieira WP, Albuquerque EN, Bianchi WA, Bonfiglioli R, Campanholo C, Carvalho HM, Costa IPD, Duarte ALP, Leite NH, Lima SA, Meirelles ES, Pereira IA, Pinheiro MM, Polito E, Resende GG, Rocha FAC, Santiago MB, Sauma MDFL, Valim V, Sampaio-barros PD. Perfil do uso de drogas modificadoras de doença no Registro Brasileiro de Espondiloartrites. Revista Brasileira de Reumatologia 2014;54:33-7. [DOI: 10.1016/j.rbr.2013.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
231 Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis 2017;23:233-43. [PMID: 28092307 DOI: 10.1097/MIB.0000000000000995] [Cited by in Crossref: 96] [Cited by in F6Publishing: 28] [Article Influence: 24.0] [Reference Citation Analysis]
232 Maggi L, Capone M, Giudici F, Santarlasci V, Querci V, Liotta F, Ficari F, Maggi E, Tonelli F, Annunziato F. CD4+CD161+ T lymphocytes infiltrate Crohn’s disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy. Int Arch Allergy Immunol. 2013;161:81-86. [PMID: 23257766 DOI: 10.1159/000343467] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
233 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
234 Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012;47:518-527. [PMID: 22375898 DOI: 10.3109/00365521.2012.660541] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 6.9] [Reference Citation Analysis]
235 Pike MC, Kelley L. Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep 2012;14:324-33. [PMID: 22580894 DOI: 10.1007/s11926-012-0261-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
236 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
237 Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018;155:1008-1011.e8. [PMID: 29981298 DOI: 10.1053/j.gastro.2018.06.077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
238 Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P. Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients. Inflamm Intest Dis 2018;2:171-9. [PMID: 30018967 DOI: 10.1159/000486676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
239 O’neill I, Scully C. Biologics in oral medicine: ulcerative disorders: Biologics: ulcerative disorders. Oral Dis 2013;19:37-45. [DOI: 10.1111/j.1601-0825.2012.01931.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
240 Carman N, Mack DR, Benchimol EI. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0623-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
241 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
242 Samaan MA, Arkir Z, Ahmad T, Irving PM. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther 2018;18:1271-9. [PMID: 30339466 DOI: 10.1080/14712598.2018.1537367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
243 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]
244 Khoury T, Ilan Y. Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. Front Immunol 2019;10:2726. [PMID: 31824506 DOI: 10.3389/fimmu.2019.02726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
245 Haider SA, Yadav A, Perry C, Su L, Akanbi O, Kudaravalli P, Tripathi N, Hashim MA, Abdelsalam M, Hussein M, Elkheshen A, Patel V, Ali SE, Lamb L, Ingram K, Mayne C, Stuffelbeam AB, Flomenhoft D, Stromberg A, Barrett TA. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820959245. [PMID: 33133239 DOI: 10.1177/1756284820959245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:309-15. [PMID: 22605668 DOI: 10.1002/ibd.23026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
247 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Savova G, Churchill S, Karlson EW, Kohane I, Liao KP, Murphy SN. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis 2016;22:880-5. [PMID: 26933751 DOI: 10.1097/MIB.0000000000000754] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
248 Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open 2014;4:e005887. [PMID: 25524543 DOI: 10.1136/bmjopen-2014-005887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
249 Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66-82. [PMID: 25729432 DOI: 10.1177/1756283x14558193] [Cited by in Crossref: 89] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
250 Park SH, Hwang SW, Kwak MS, Kim WS, Lee JM, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS. Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study. Dig Dis Sci. 2016;61:2060-2067. [PMID: 26971089 DOI: 10.1007/s10620-016-4105-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
251 Bonaz B, Picq C, Sinniger V, Mayol JF, Clarençon D. Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil. 2013;25:208-221. [PMID: 23360102 DOI: 10.1111/nmo.12076] [Cited by in Crossref: 156] [Cited by in F6Publishing: 140] [Article Influence: 17.3] [Reference Citation Analysis]
252 Renna S, Orlando A, Cottone M. Comparing medical treatments for Crohn's disease. J Comp Eff Res 2013;2:135-49. [PMID: 24236556 DOI: 10.2217/cer.13.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
253 Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina R, Andriulli A. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci 2020;65:1767-76. [PMID: 31722059 DOI: 10.1007/s10620-019-05904-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Kim H. Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon? Ann Coloproctol 2015;31:121-2. [PMID: 26361612 DOI: 10.3393/ac.2015.31.4.121] [Reference Citation Analysis]
255 Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M, Palatka K, Nyári T, Bálint A, Lőrinczy K, Wittmann T. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013;37:225-33. [DOI: 10.1111/apt.12160] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 6.0] [Reference Citation Analysis]
256 Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011;5:679-84. [PMID: 22017695 DOI: 10.1586/egh.11.81] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
257 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 156] [Cited by in F6Publishing: 136] [Article Influence: 22.3] [Reference Citation Analysis]
258 Lin WC, Chou JW, Yen HH, Hsu WH, Lin HH, Lin JK, Chuang CH, Huang TY, Wang HY, Wei SC, Wong JM. Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intest Res 2017;15:487-94. [PMID: 29142516 DOI: 10.5217/ir.2017.15.4.487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
259 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
260 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
261 Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, D'haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel J, Panaccione R. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013;7:653-69. [DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
262 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies: . Inflammatory Bowel Diseases 2016;22:1999-2015. [DOI: 10.1097/mib.0000000000000772] [Cited by in Crossref: 67] [Cited by in F6Publishing: 21] [Article Influence: 11.2] [Reference Citation Analysis]
263 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
264 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
265 Gecse KB, Lakatos PL. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects. Drugs 2016;76:1413-20. [DOI: 10.1007/s40265-016-0638-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
266 Szabó D, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh Á, Veres G. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease. Journal of Crohn's and Colitis 2014;8:747-55. [DOI: 10.1016/j.crohns.2013.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
267 Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015;13:1197-1200. [PMID: 25460565 DOI: 10.1016/j.cgh.2014.11.020] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
268 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
269 Martin-Subero M, Anderson G, Kanchanatawan B, Berk M, Maes M. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr 2016;21:184-98. [PMID: 26307347 DOI: 10.1017/S1092852915000449] [Cited by in Crossref: 89] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
270 Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017;18. [PMID: 28617319 DOI: 10.3390/ijms18061276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
271 Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015;55 Suppl 3:S39-S50. [PMID: 25707962 DOI: 10.1002/jcph.374] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
272 Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473-1485. [PMID: 22849511 DOI: 10.1517/14712598.2012.711308] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
273 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
274 García Ruiz de Morales JM, Pascual-salcedo D, Llinares Tello F, Valor Méndez L. Tratamiento con fármacos anti-TNF: utilidad de la monitorización de niveles de fármaco y anticuerpos antifármaco en la práctica clínica. Medicina Clínica 2016;147:410-6. [DOI: 10.1016/j.medcli.2016.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]